Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates

Clinical and Translational Science

Volumn 11, Issue 2, 2018, Pages 200-207

  Kurtz, Caroline ^a   Denney, William S ^b   Blankstein, Larry ^a   Guilmain, Sarah E ^a   Machinani, Suman ^a   Kotula, Jonathan ^a   Saha, Saurabh ^c   Miller, Paul ^a   Brennan, Aoife M ^a  

^a SYNLOGIC   (United States)

^b Human Predictions   (United States)

^c 400 Technology Square   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; ARGININE; PROBIOTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL MICROBIOME; BACTERIAL STRAIN; COLONY FORMING UNIT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE; FECES ANALYSIS; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM CONCENTRATION; NONHUMAN; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; ANIMAL; BIOLOGICAL THERAPY; CLINICAL TRIAL; FECES; GENETICS; INBORN ERROR OF METABOLISM; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PRIMATE; PROCEDURES; PROSPECTIVE STUDY; TRANSGENIC MICROORGANISM; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ARGININE; BIOLOGICAL THERAPY; ESCHERICHIA COLI; FECES; FEMALE; HEALTHY VOLUNTEERS; HOST MICROBIAL INTERACTIONS; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLISM, INBORN ERRORS; MICROBIOTA; MICROORGANISMS, GENETICALLY-MODIFIED; MIDDLE AGED; MODELS, ANIMAL; PRIMATES; PROBIOTICS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85044372344     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12528     Document Type: Article

References (23)

1. Wassenaar, T.M. Insights from 100 years of research with probiotic E. coli. Eur. J. Microbiol. Immunol. 6, 147–161 (2016).
2. Joeres-Nguyen-Xuan, T.H., Boehm, S.K., Joeres, L., Schulze, J. & Kruis, W. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflamm. Bowel Dis. 16, 256–262 (2010).
3. Lata, J. et al. Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonization, endotoxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis. Vnitr. Lek. 52, 215–219 (2006).
4. Wassenaar, T.M., Beimfohr, C., Geske, T. & Zimmermann, K. Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation. Benef. Microbes 5, 367–375 (2014).
5. Cukrowska, B., Lodlnová-Zádnlková, R., Enders, C., Sonnenborn, U., Schulze, J. & Tlaskalová-Hogenová, H. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand. J. Immunol. 55, 204–209 (2002).
6. Prilassnig, M., Wenisch, C., Daxboeck, F. & Feierl, G. Are probiotics detectable in human feces after oral uptake by healthy volunteers? Wien. Klin. Wochenschr. 119, 456–462 (2007).
7. Mutaflor Kaps. Prescribing Information, Ardeypharm GmbH, August 2015. (English translation from German: Mutaflor Kaps. Fachinformation, Ardeypharm GmbH, August 2015).
8. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org.
9. Denney, W.S., Duvvuri, S. & Buckeridge, C. Simple, automatic noncompartmental analysis: the PKNCA R package. J. Pharmacokinet. Pharmacodyn. 42, 11–107, S65. R package version 0.8.1. Available at: . (2015).
10. Stan Development Team. rstanarm: Bayesian applied regression modeling via Stan. R package version 2.14.1. Available at: http://mc-stan.org (2017).
11. DeSesso, J. & Williams, A. Chapter 21. Contrasting the gastrointestinal tracts of mammals: factors that influence absorption. Annu. Rep. Med. Chem. 43, 353–371 (2008).
12. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419–424 (2012).
13. Rondadelli, M., Faliva, M.A., Perna, S., Giacosa, A., Peroni, G. & Castellazzi, A.M. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut Microbes 22, 1–23 (2017).
14. Kukkonen, K. et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 119, 192–198 (2007).
15. Venturi, A. et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1103–1108 (1999).
16. Reister, M. et al. Complete genome sequence of the gram-negative probiotic Escherichia coli strain Nissle 1917. J. Biotechnol. 10, 106–107 (2014).
17. Cress, B.F., Linhardt, R.J. & Koffas, M.A.G. Draft genome sequence of Escherichia coli strain Nissle 1917 (serovar O6:K5:H1). Genome Announc. 1, e00047-13 (2013).
18. Mordenti, J. Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75, 1028–1040 (1986).
19. Krammer, H.J. et al. [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients]. Z. Gastroenterol. 44, 651–656 (2006).
20. Rose, C., Parker, A., Jefferson, B. & Cartmell, E. The characterization of feces and urine: a review of the literature to inform advanced treatment technology. Crit. Rev. Environ. Sci. Technol., 45, 1827–1879 (2015).
21. McCord, A.I. et al. Fecal microbiomes of non-human primates in Western Uganda reveal species-specific communities largely resistant to habitat perturbation. Am. J. Primatol. 76, 347–354 (2014).
22. Amato, K.R. et al. Variable responses of human and non-human primate gut microbiomes to a Western diet. Microbiome 3, 53 (2015).
23. Gorzelak, M.A., Gill, S.K., Tasnim, N., Ahmadi-Vand, Z., Jay, M. & Gibson, D.L. Methods for improving human gut microbiome data by reducing variability through sample processing and storage of stool. PLoS One 10(8),e0134802 (2015).